Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459966 | 0.82 | HRH3 (0.55) | HRH3MAPK1HTTDRD3HTR6 | |
| SCHEMBL5457089 | 0.81 | TSHR (0.57) | HRH3TSHRMAPK1HTTDRD3 | |
| SCHEMBL5463839 | 0.81 | HRH3 (0.60) | HRH3DRD3HTR6DRD2CYP2D6 | |
| SCHEMBL5472280 | 0.81 | HRH3 (0.59) | HRH3MAPK1HTTDRD3HTR6 | |
| SCHEMBL5451040 | 0.80 | HRH3 (0.49) | HRH3DRD3HTR6DRD2CYP2D6 | |
| SCHEMBL5461526 | 0.80 | HRH3 (0.55) | HRH3DRD3HTR6DRD2MAPT | |
| SCHEMBL5460678 | 0.79 | MCOLN3 (0.54) | HRH3TSHRMAPK1DRD3HTR6 | |
| SCHEMBL5453406 | 0.79 | HRH3 (0.50) | HRH3DRD3HTR6DRD2CYP2D6 | |
| SCHEMBL5462288 | 0.79 | HRH3 (0.59) | HRH3MAPK1HTTDRD3HTR6 | |
| SCHEMBL5458837 | 0.78 | KMT2A (0.53) | HRH3TSHRMAPK1HTTDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | HRH3 38/4885RAB9A 3597/4885TNF 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.